After seeing telehealth visits skyrocket 3,700% in April over March—most of them COVID-related—UPMC is touting its use of AI to help patients retain and apply doctors’ guidance offered during virtual visits.

Understood as a virtual army in the war against COVID-19, AI has vast stockpiles of potential weaponry with which to wage many a battle. That’s the good news.

COVID-19 isn’t only keeping patients home when they should be seeing their doctors. It’s also keeping clinical investigators from moving ahead with their research.

The lab’s leaders are pledging to support innovators in various industries—including healthcare—who will have a hand in the rise of 5G technology.

Clinicians equipped with machine learning can, in theory, apply what works for one patient to the care of another—and another, and another—and so on.

U.S. healthcare leadership missed opportunities for optimally promoting public health fairly early on in the present pandemic.

Notching its fifth go-ahead from the FDA, an Israel-based AI startup has received the agency’s 510(k) clearance to market software that automatically identifies signs of compression fractures in the spine.

AI, blockchain and the internet of things are among the digital tributaries poised to feed the flow of the field’s collective input.

AI startup Immunai has announced it’s working to map the entire human immune system with $20 million in seed funding to push the project along.

An experimental set of algorithms has achieved accuracy of 70% to 80% at predicting which of 53 COVID-positive patients at two hospitals in China would get the sickest.